The effect of an oral administration of Lactobacillus casei strain shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat.
The preventive effect of oral administration of viable Lactobacillus casei strain Shirota (LcS) on azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) and colon cancers in the rat was investigated. The study consisted of two experiments; in a short-term experiment (Exp-I), the inhibitory effect of 8- and 12-week treatments with LcS. Forty rats each received weekly a subcutaneous injection of AOM at a dose of 15 mg/kg of body weight for 5 weeks. Eight and twelve weeks after the start of the carcinogen treatment, each subgroup of rats were sacrificed, and the colon and the mesenteric lymph nodes (MLN) were removed. The number of ACFs and the surface marker of lymphocytes derived from the MLN were investigated. The large ACF (those comprising four or more aberrant crypts per focus) had significantly decreased in the rats which had consumed the LcS diet. And oral administration of viable LcS significantly recovered CD8 positive lymphocytes to the levels in the control group. In a long-term experiment (Exp-II), 30 rats each received weekly a subcutaneous injection of AOM at a dose of 7. 4 mg/kg of body weight for 10 weeks. Twenty-five weeks after the start of the carcinogen treatment, each subgroup of rats were sacrificed, and the colon were removed. The number and incidence of colon cancers were investigated. The number of rats with colon cancers and the number of colon cancers per rat, were significantly decreased in the rats which had consumed the LcS diet. LcS inhibited chemically-induced colon carcinogenesis in the rat. CD8 positive T lymphocytes may play a key role in the preventive effect against colon carcinogenesis.
Yamazaki
K
K
Second Department of Surgery, School of Medicine, Showa University, Shinagawa-ku, Tokyo 142-8666, Japan.
Tsunoda
A
A
Sibusawa
M
M
Tsunoda
Y
Y
Kusano
M
M
Fukuchi
K
K
Yamanaka
M
M
Kushima
M
M
Nomoto
K
K
Morotomi
M
M
D000284:Administration, Oral; D000818:Animals; D001397:Azoxymethane / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D001835:Body Weight / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D002273:Carcinogens / Q000037:antagonists & inhibitors; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D007780:Lacticaseibacillus casei / Q000145:classification; D008198:Lymph Nodes / Q000166:cytology / Q000276:immunology; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology; D008297:Male; D011230:Precancerous Conditions / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control*; D019936:Probiotics / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
D002273:Carcinogens; C053327:azoxyethane; D001397:Azoxymethane